SC 13D/A

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)

 

 

OPGEN, INC.

(Name of Issuer)

Common Stock, $0.01 par value

(Title of Class of Securities)

68373L208

(CUSIP Number)

William Taranto, President

Merck Global Health Innovation Fund, LLC

One Merck Drive

Whitehouse Station, NJ 08889

908-423-6551

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

July 30, 2018

(Date of Event which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 68373L208  

 

  1.   

Names of Reporting Persons.

 

Merck Global Health Innovation Fund, LLC

  2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ☐        (b)  ☐

 

  3.  

SEC Use Only

 

  4.  

Source of Funds (See Instructions)

 

OO

  5.  

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  6.  

Citizenship or Place of Organization

 

Delaware

Number of shares beneficially owned by each reporting person with

 

     7.    

Sole Voting Power

 

491,927*

     8.   

Shared Voting Power

 

0

     9.   

Sole Dispositive Power

 

491,927*

   10.   

Shared Dispositive Power

 

0

11.  

Aggregate amount beneficially owned by each reporting person

 

491,927*

12.  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

☐  

13.  

Percent of Class Represented by Amount in Row (11)

 

7.8**%

14.  

Type of Reporting Person (See Instructions)

 

OO

 

*

Includes (i) 59,159 shares owned previously owned; (ii) 48,000 shares of common stock and warrants to acquire 36,000 shares of common stock acquired at the First Closing pursuant to that certain Amended and Restated Securities Purchase Agreement dated May 18, 2016 (the “A&R Purchase Agreement”) which occurred on May 19, 2016; (iii) 109,377 shares of common stock and warrants to acquire 82,033 shares of common stock acquired at a Second Closing which occurred on June 27, 2016; (iv) a warrant to acquire 13,120 shares of common stock acquired in connection with amendment and restatement of a senior secured promissory note; and (v) 144,238 shares of common stock issued which represents payment for interest accrued on the Second Amended & Restated Senior Promissory Note through July 14, 2018.

**

Such percentage was calculated based upon an aggregate of 6,342,430 Issuer shares of common stock outstanding, consisting of (i) 6,211,277 Issuer shares of common stock outstanding as of August 1, 2018; and (ii) 131,153 shares of common stock able to be acquired by the Reporting Person upon exercise of warrants or stock options.


CUSIP No. 68373L208  

 

  1.   

Names of Reporting Persons.

 

Merck Sharp & Dohme Corp.

  2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ☐        (b)  ☐

 

  3.  

SEC Use Only

 

  4.  

Source of Funds (See Instructions)

 

WC

  5.  

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  6.  

Citizenship or Place of Organization

 

New Jersey

Number of shares beneficially owned by each reporting person with

 

     7.    

Sole Voting Power

 

491,927*

     8.   

Shared Voting Power

 

0

     9.   

Sole Dispositive Power

 

491,927*

   10.   

Shared Dispositive Power

 

0

11.  

Aggregate amount beneficially owned by each reporting person

 

491,927*

12.  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

☐  

13.  

Percent of Class Represented by Amount in Row (11)

 

7.8**%

14.  

Type of Reporting Person (See Instructions)

 

CO

 


CUSIP No. 68373L208  

 

  1.   

Names of Reporting Persons.

 

Merck & Co., Inc.

  2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ☐        (b)  ☐

 

  3.  

SEC Use Only

 

  4.  

Source of Funds (See Instructions)

 

OO

  5.  

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  6.  

Citizenship or Place of Organization

 

New Jersey

Number of shares beneficially owned by each reporting person with

 

     7.    

Sole Voting Power

 

491,927*

     8.   

Shared Voting Power

 

0

     9.   

Sole Dispositive Power

 

491,927*

   10.   

Shared Dispositive Power

 

0

11.  

Aggregate amount beneficially owned by each reporting person

 

491,927*

12.  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

☐  

13.  

Percent of Class Represented by Amount in Row (11)

 

7.8**%

14.  

Type of Reporting Person (See Instructions)

 

CO

 


Introductory Note

This Amendment No. 4 (this “Amendment No. 4”) amends the statement on Schedule 13D filed on July 23, 2015, amended by Amendment No. 1 filed on May 31, 2016, amended by Amendment No. 2 filed on June 29, 2016 and Amendment No. 3 filed on February 8, 2018 (the “Schedule 13D”), with respect to shares of common stock, par value $0.01 per share (the “Common Stock”) of OpGen, Inc., a Delaware corporation (the “Issuer” or the “Company”). This Amendment No. 4 is being filed to report: (i) the issuance of 144,238 shares of the Company’s Common Stock issued to the Reporting Persons which represents payment for interest accrued on the Second Amended & Restated Senior Promissory Note through July 14, 2018.

Item 3. Source and Amount of Funds or Other Consideration.

Item 3 is amended and restated in its entirety as follows:

No borrowed funds were used in the purchase.

Item 4. Purpose of Transaction.

Item 4 is amended and restated in its entirety as follows:

The information set forth under Items 3 and 6 is hereby incorporated by reference.

All of the securities of the Issuer acquired as described in Item 6 were acquired for investment purposes. The Reporting Persons intend to review on a continuing basis the investment in the Issuer. Based on such review, the Reporting Persons may acquire, or cause to be disposed, such securities at any time or formulate other purposes, plans or proposals regarding the Issuer or any of its securities, to the extent deemed advisable in light of general investment and trading policies of the Reporting Persons, the Issuer’s business, financial condition and operating results, general market and industry conditions or other factors.

Dr. David Rubin, an employee of Merck, continues to serve on the board of directors of the Issuer. Except as otherwise described in this Schedule 13D, or pursuant to the transactions contemplated by the Purchase Agreement, none of the Reporting Persons nor, to the best knowledge of the Reporting Persons, any of the persons listed on Schedule A to this Schedule 13D, currently has any plans or proposals that would result in:

 

  (a)

The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

 

  (b)

An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

 

  (c)

A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

 

  (d)

Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the Board;

 

  (e)

Any material change in the present capitalization or dividend policy of the Issuer;

 

  (f)

Any other material change in the Issuer’s business or corporate structure including but not limited to, if the Issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by section 13 of the Investment Company Act of 1940;

 

  (g)

Changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;


  (h)

Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

 

  (i)

A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or

 

  (j)

Any action similar to any of those enumerated above.

However, as part of the ongoing evaluation of this investment and investment alternatives, the Reporting Persons may consider such matters and, subject to applicable law, may formulate a plan with respect to such matters, and, from time to time, may hold discussions with or make formal proposals to management or the Board of the Issuer, other stockholders of the Issuer or other third parties regarding such matters.

Item 5. Interest in Securities of the Issuer.

Item 5 is amended and restated in its entirety as follows:

(a) The Reporting Persons may be deemed to beneficially own 491,927 shares of Common Stock of which 131,153 of the 491,927 shares of Common Stock represent shares that MGHIF has the right to acquire from the Issuer pursuant to Warrants. The Common Stock voting rights represent 7.8% of the total number of shares of common stock treated as outstanding for purposes of such vote. The ownership percentages set forth in this Schedule 13D, is based on information provided by the Issuer. As a result of their direct and indirect ownership of MGHIF, each of MSD and Merck may be deemed to share the Common Stock voting rights held in the name of the Purchaser.

(b) Each of the Reporting Persons has the power to vote or direct the vote of the 360,774 votes that may be cast in actions taken by common stockholders as a result of the shares of Common Stock held in the name of the MGHIF. None of the Reporting Persons has sole or shared power to direct the disposition of any shares of Common Stock.

(c) To the best knowledge of the Reporting Persons, none of the Reporting Persons nor the individuals named in Schedule A to this Schedule 13D has effected a transaction in shares of the Issuer during the past 60 days.

(d) Other than the Reporting Persons, no other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the Reporting Persons’ securities.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

Item 6 is hereby amended by inserting the following paragraphs at the end thereof:

On June 11, 2018, OpGen, Inc. (the “Company” or “OpGen”) executed an Allonge (the “Allonge”) to its Second Amended and Restated Senior Secured Promissory Note, dated June 28, 2017, with a principal amount of $1,000,000 (the “Note”) issued to Merck Global Health Innovation Fund, LLC (“MGHIF”). The Allonge modified the Note to (1) provide that accrued and unpaid interest of $285,512.22 due as of July 14, 2018, the original maturity date, will be paid through the issuance of shares of OpGen’s common stock in a private placement transaction; and (2) revision and extension of the maturity date for payment of the Note to six semi-annual payments of $166,666.67 plus accrued and unpaid interest beginning on January 2, 2019 and ending on July 1, 2021 (the “Final Maturity Date”). The number of shares of common stock issued was determined after July 14, 2018 based on the 30-day average volume-weighted closing price of OpGen’s common stock, and issued on July 30, 2018. The interest rate remains at 10%, subject to increase to 15% upon an event of default. The Note is secured by all of the assets, including intellectual property, of the Company.


The foregoing is subject to and qualified by the terms and conditions contained in the Allonge, dated June 11, 2018, to the Second Amended and Restated Senior Secured Promissory Note, dated June 28, 2017, with a principal amount of $1,000,000 issued by OpGen, Inc. to Merck Global Health Innovation Fund, LLC, a copy of which is incorporated by reference to the Schedule 13D as Exhibit 10.


Item 7. Material to be Filed as Exhibits.

Item 7 is hereby amended and supplemented by inserting the following at the end thereof:

 

10.

Allonge, dated June 11, 2018, to the Second Amended and Restated Senior Secured Promissory Note, dated June 28, 2017, with a principal amount of $1,000,000 issued by OpGen, Inc. to Merck Global Health Innovation Fund, LLC (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed by OpGen, Inc. with the Securities and Exchange Commission on June 11, 2018).


Signatures

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated this 9th day of August, 2018.

 

MERCK GLOBAL HEALTH INNOVATION FUND, LLC

 

By:  

/s/ Jon Filderman

Name:   Jon Filderman
Title:  

Secretary

 

MERCK SHARP & DOHME CORP.

 

By:  

/s/ Faye C. Brown

Name:   Faye C. Brown

Title:

 

  Assistant Secretary

MERCK & CO., INC.

 

By:  

/s/ Faye C. Brown

Name:   Faye C. Brown
Title:   Senior Assistant Secretary


EXHIBIT INDEX

Item 7. Material to be Filed as Exhibits.

 

10.

Allonge, dated June 11, 2018, to the Second Amended and Restated Senior Secured Promissory Note, dated June 28, 2017, with a principal amount of $1,000,000 issued by OpGen, Inc. to Merck Global Health Innovation Fund, LLC (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed by OpGen, Inc. with the Securities and Exchange Commission on June 11, 2018).


SCHEDULE A

The name, present principal occupation or employment, and the name, principal business and address of any corporation or other organization in which such employment is conducted, of each of the executive officers and directors of each of the Reporting Persons is set forth below.

MERCK GLOBAL HEALTH INNOVATION FUND, LLC

EXECUTIVE OFFICERS AND DIRECTORS

 

Name

  

Principal Occupation

  

Business Address

  

Citizenship

Donna Daidone-Yahara    Assistant Vice President, Finance   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Robert Davis    Manager / Vice President   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Katie Fedosz    Assistant Secretary   

2000 Galloping Hill Road

Kenilworth NJ, 07033

   USA
Jon Filderman    Manager/ Secretary   

2000 Galloping Hill Road

Kenilworth NJ, 07033

   USA
Julie Gerberding    Manager   

2000 Galloping Hill Road

Kenilworth NJ, 07033

   USA
Michael Klobuchar    Manager   

2000 Galloping Hill Road

Kenilworth NJ, 07033

   USA
Timothy Dillane    Assistant Treasurer   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Juanita Lee    Assistant Treasurer   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Salvatore Lombardo    Vice President, Tax   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Mark E. McDonough    Senior Vice President and Treasurer   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Faye C. Brown    Assistant Secretary   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Joseph Miletich    Manager   

126 E. Lincoln Avenue

Rahway, NJ 07065

   USA
Joseph Promo    Assistant Treasurer   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Adam Schechter    Manager   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Michael G. Schwartz    Assistant Treasurer   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
William J. Taranto    Manager / President   

One Merck Drive,

Whitehouse Station, NJ 08889

   USA
Donna Daidone-Yahara    Assistant Vice President, Finance   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA


MERCK SHARP & DOHME CORP.

EXECUTIVE OFFICERS AND DIRECTORS

 

Name

  

Principal Occupation

  

Business Address

  

Citizenship

Timothy Dillane    Assistant Treasurer   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Katie Fedosz    Assistant Secretary   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Jon Filderman    Director   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Rita Karachun    Director / President   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Juanita Lee    Assistant Treasurer   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Salvatore Lombardo    Assistant Secretary, Tax   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Mark E. McDonough   

Director /

Senior Vice President and Treasurer

  

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Jerome Mychalowych    Vice President, Tax   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Faye C. Brown    Assistant Secretary   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Geralyn Ritter    Secretary   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Michael G. Schwartz    Assistant Treasurer   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA


MERCK & CO., INC.

OFFICERS

 

Name

  

Principal Occupation

  

Business Address

  

Citizenship

Kenneth C. Frazier    Chairman, President and Chief Executive Officer / Director, Merck & Co., Inc.   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Sanat Chattopadhyay    Executive Vice President and President, Merck Manufacturing Division (“MMD”), Merck & Co., Inc.   

One Merck Drive,

Whitehouse Station, NJ 08889-0100

   USA
Robert Davis    Executive Vice President, Chief Financial Officer and Global Services, Merck & Co., Inc.   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Richard R. DeLuca, Jr.    Executive Vice President and President, Merck Animal Health   

Giralda Farms 2

Madison, NJ 07940

   USA
Faye C. Brown    Senior Assistant Secretary, Merck & Co., Inc.   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Julie Gerberding    Executive Vice President and Chief Patient Officer, for Strategic Communications, Global Public Policy and Population Health, Merck & Co., Inc.   

351 N. Sumneytown Pike

North Wales, PA 19454

   USA
Mirian M. Graddick-Weir    Executive Vice President, Human Resources, Merck & Co., Inc.   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Rita Karachun    Senior Vice President Finance – Global Controller, Merck & Co., Inc.   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Timothy Dillane    Assistant Treasurer, Merck & Co., Inc.   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Juanita Lee    Assistant Treasurer, Merck & Co., Inc.   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Mark McDonough    Senior Vice President and Treasurer, Merck & Co., Inc.   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Roger Perlmutter    Executive Vice President and President, Merck Research Laboratories   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Geralyn Ritter    Senior Vice President, Corporate Secretary and Assistant General Counsel, Merck & Co., Inc.   

2000 Galloping Hill Road

Kenilworth, NJ 07033

  
Adam H. Schechter    Executive Vice President and President, Global Human Health, Merck & Co., Inc.   

600 Corporate Drive,

Lebanon, NJ 08833

   USA
Michael G. Schwartz    Assistant Treasurer, Merck & Co., Inc.   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Ashley B. Watson    Senior Vice President and Chief Ethics and Compliance Officer   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Jennifer Zachary    Executive Vice President and General Counsel, Merck & Co., Inc.   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA


MERCK & CO., INC.

DIRECTORS

 

Kenneth C. Frazier    Chairman, President and Chief Executive Officer, Merck & Co., Inc.   

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Leslie A. Brun    Chairman and Chief Executive Officer, Sarr Group, LLC   

435 Devon Park Drive,

700 Building,

Wayne, PA 19087

   USA
Thomas R. Cech    Investigator, Howard Hughes Medical Institute and Faculty, University of Colorado.   

University of Colorado,

University of Colorado at Boulder

3415 Colorado Avenue, JSCBB

Boulder, CO 80309-0215

   USA
Thomas H. Glocer    Retired Chief Executive Officer, Thomson Reuters Corporation   

6 East 43rd Street, 25th Floor

New York, NY 10022

   USA
Pamela J. Craig    Former Chief Financial Officer, Accenture, plc   

c/o Merck & Co., Inc.

2000 Galloping Hill Road

Kenilworth, NJ 07033

   USA
Rochelle B. Lazarus    Chairman Emeritus, Ogilvy & Mather   

636 11th Avenue,

New York, NY 10036-2010

   USA
John H. Noseworthy, M.D.    President and Chief Executive Officer, Mayo Clinic   

Mayo Clinic

200 First Street SW

Rochester, MN 55905

   USA
Paul B. Rothman, M.D.    Dean of Medical Faculty and Vice President for Medicine, The Johns Hopkins University, and CEO John Hopkins Medicine    733 N. Broadway, Suite 100 Baltimore, MD 21205-2196    USA
Patricia F. Russo    Chairman, Hewlett Packard Enterprise Company   

Hewlett Packard Enterprise

300 Hanover Street – Mailstop 1050

Palo Alto, CA 94304

   USA
Craig B. Thompson    President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center   

Memorial Sloan-Kettering Cancer Center, 1275 York Avenue,

Room M110

New York, NY 10065

   USA
Inge G. Thulin    Executive Chairman, 3M Company   

3M Corporate Headquarters

3M Center

St. Paul, MN 55144-1000

   USA
Wendell P. Weeks    President, Chairman and Chief Executive Officer, Corning Incorporated   

1 Riverfront Plaza,

Corning, NY 14831-0001

   USA
Peter C. Wendell    Managing Director, Sierra Ventures   

1400 Fashion Island Blvd.

Suite 1010

San Mateo, CA 94404

   USA